ArticleMolecular medicine reports2020
MicroRNA‑29a promotes the neural differentiation of rat neural stem/progenitor cells by targeting KLF4.
Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense.Theranostics · 2025Article
- Krüppel-like factors family in health and disease.MedComm · 2024Review
- Downregulation of miR-29a as a possible diagnostic biomarker for schizophrenia.Molecular biology reports · 2024Article
- Transcription factors are potential therapeutic targets in epilepsy.Journal of cellular and molecular medicine · 2022Review
- Micro-RNAs: A safety net to protect hematopoietic stem cell self-renewal.Wiley interdisciplinary reviews. RNA · 2022Review
- MicroRNA-Based Diagnosis and Therapeutics for Vascular Cognitive Impairment and Dementia.Frontiers in neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neural stem/progenitor cells (NSPCs) remain in the mammalian brain throughout life, where they have the ability to self‑renew and generate different types of cell in the central nervous system (CNS). Therefore, NSPCs may be a potential novel therapeutic strategy following damage to the CNS. Previous research has reported that microRNA (miR)‑29a served an important role in regulating cell proliferation, differentiation and survival; however, to the best of our knowledge, little is known of the effect of miR‑29a in neural differentiation. The present study aimed to investigate the effect of miR‑29a on the differentiation of NSPCs, determined via RNA interference, immunostaining, reverse transcription-quantitative PCR and western blotting. The present study discovered that the expression levels of miR‑29a were significantly upregulated in a time‑dependent manner during neural differentiation. Immunostaining showed that overexpression of miR‑29a promoted neural differentiation, which manifested in increased expression levels of neuron‑specific class III β‑tubulin (Tuj1); however, miR‑29a had no effect on neuroglial differentiation. The expression levels of Kruppel‑like factor 4 (KLF4) were downregulated following overexpression of miR‑29a, whereas the inhibition of miR‑29a demonstrated the opposite effect. These results suggested that the overexpression of miR‑29a may promote neural differentiation in cultured rat NSPCs by decreasing the expression levels of KLF4. Thus indicating that targeting KLF4, a crucial regulatory factor for the maintenance of stemness, may be a potential underlying mechanism of action for miR‑29a. In conclusion, the findings of the present study identified a potential mechanism of action for miR‑29a in NSPC differentiation and provided a novel insight into the treatment strategies for CNS damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.